Cyxone receives patent approval from the US for the salt forms of the compound rabeximod

Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the company has obtained granted status for the US patent application 17/891,462 entitled Rabeximod Compounds from the United States Patent and Trademark Office (USPTO).

The application covers the protection of salt forms of the compound rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis. The patent will be valid until 2042.

”We are delighted to receive the final approval for this important patent. It is an essential fundament for the future development and commercialization of rabeximod”, says Carl-Magnus Högerkorp, CEO at Cyxone.

Contact
Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com

About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com